Response of normal subjects to a single 2-milligram dose of glucagon administered intramuscularly.
Recently there has been increased interest in glucagon because in human radiographic and endoscopic studies it has been reported to relax the gallbladder, stomach, small bowel and colon. These results suggest it may be preferable as a diagnostic aid for these procedures. Therefore, we believed it important to assess the safety, and clinical laboratory responses after glucagon is given to normal subjects. Twenty normal subjects received 2 mg of glucagon and placebo intramuscularly at daily intervals, double-blind and crossover. After glucagon there was an increase in the WBC, bands, neutrophiles, fasting blood sugar, glucagon and insulin, and a decrease in the lymphocytes. There was no change in the pulse rate or blood pressure with minimal reports of side effects. These results tend to confirm other reports that glucagon is one of the stress hormones. Glucagon is remarkably safe and produces few, mild and transient side effects, not much greater than placebo.
D000328:Adult; D005934:Glucagon / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D013006:Growth Hormone / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D007328:Insulin / Q000097:blood; D009638:Norepinephrine / Q000652:urine; D013997:Time Factors
D007328:Insulin; D013006:Growth Hormone; D005934:Glucagon; D009638:Norepinephrine